Articles published by ENYO Pharma

ENYO Pharma Announces Completion and Topline Data From Phase 2 Alpestria-1 Clinical Study in Alport Syndrome Demonstrating Vonafexor Reverses Kidney Function Decline and Has Sustained Therapeutic Benefit

January 08, 2026

From ENYO Pharma

Via Business Wire

ENYO Pharma Announces Completion of Series C Financing With Vesalius Biocapital and Continued Progress of Its ALPESTRIA-1 Clinical Phase 2 Study in Alport Syndrome Patients

June 12, 2025

From ENYO Pharma

Via Business Wire

ENYO Pharma Announces a €39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Trial for Patients With Alport Syndrome

January 03, 2024

From ENYO Pharma

Via Business Wire

ENYO Pharma Announces Two Vonafexor Data Presentations at AASLD The Liver Meeting

November 03, 2021

From ENYO Pharma

Via Business Wire

ENYO Pharma Announces 16 Weeks Vonafexor (EYP001) Top-Line Interim Results from Two on-going Phase 2a Studies in Chronic Hepatitis B Patients

July 30, 2021

From ENYO Pharma

Via Business Wire

ENYO Pharma Announces Positive Vonafexor (EYP001) Results for the LIVIFY Phase 2a Study in F2-F3 NASH Patients over 12 weeks

July 28, 2021

From ENYO Pharma

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.